ReviewJournal of translational medicine2026
Overcoming therapeutic challenges in acute myeloid leukemia: active targeting strategies by nano-drug delivery systems.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploiting Metabolic Vulnerabilities in Acute Myeloid Leukemia: Rationale and Evidence for Combining Metabolic Modulators with Conventional Chemotherapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute myeloid leukemia (AML) is a highly aggressive hematological malignancy characterized by poor overall survival and high relapse rates. The standard chemotherapy remains the conventional “7+3” regimens, while the suboptimal pharmacokinetics and significant systemic toxicity in AML present ongoing challenges to long-term disease control. Nano-drug delivery systems (NDDSs) have emerged as a promising strategy to overcome these barriers by enabling enhanced drug stability, targeted delivery, and specific distribution. Although several NDDS-based therapies have been approved by FDA, the clinical translation of nanomedicine in AML remains limited. This is largely due to the unique pathophysiology of AML, which lacks the vascular structures found in solid tumors, resulting in a limited and atypical enhanced permeability and retention (EPR) effect. Active targeting strategies, including antibody, aptamer, and peptide-based ligand modifications, offer a compelling approach to improve cellular specificity and therapeutic efficacy.
methodsIn this review, we provide a comprehensive overview of NDDSs engineered for AML, focusing on recent advances in active targeting approaches, their mechanistic advantages, and translational challenges.
resultsCurrent active-targeting NDDSs in AML generally follow two major directions. One direction focuses on surface receptors that are aberrantly overexpressed on AML cells, thereby improving payload specificity. The other direction focuses on bone marrow (BM)-targeted nanocarriers that utilize cell homing mechanisms and disease-associated markers of the BM microenvironment.
conclusionNDDSs designed for different targets, carrier materials, and release mechanisms have demonstrated improved pharmacodynamic effects, but they remain at the preclinical stage. Based on a summary of the current challenges facing NDDSs, this review further discusses key directions for next-generation system design, such as the development of personalized carriers, reduction of off-target effects, and more effective delivery to leukemia stem cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.